Company Overview
Abbott Laboratories delivered impressive Q1 2026 earnings on April 16th—just four days ago—reporting sales of $10.4 billion (up 9% year-over-year) and earnings per share of $1.26 that beat analyst expectations of $1.19. The diversified healthcare company demonstrated strength across all four business segments, with medical devices (particularly diabetes care) leading growth at 13% as the FreeStyle Libre continuous glucose monitoring system continues gaining global market share.
What makes Abbott particularly compelling right now is the FreeStyle Libre momentum revealed during the April 16th earnings call. CEO Robert Ford highlighted that FreeStyle Libre sales reached $1.8 billion in Q1 (up 25% year-over-year), with the recent launch of Libre Rio—an over-the-counter version requiring no prescription—expanding the addressable market from 8 million insulin-dependent diabetics to over 100 million Type 2 diabetics globally. Management disclosed that Libre Rio generated $150+ million in sales during its first two months on the market, suggesting the OTC strategy is resonating with consumers.
Key Technical and Fundamental Drivers
Fresh Earnings Beat → April 16th Results
Abbott reported Q1 2026 results just four days ago showing $10.4B sales (up 9% YoY), $1.26 EPS (beating $1.19 estimates), with medical devices segment growing 13%.
FreeStyle Libre Explosion → $1.8B Quarterly
FreeStyle Libre CGM sales reached $1.8 billion in Q1 (up 25% YoY), with the franchise on pace to exceed $7+ billion annually as global adoption accelerates.
OTC Launch Success → Libre Rio $150M
Libre Rio over-the-counter CGM launched in Q4 2025 generated $150+ million in first two months, expanding market beyond insulin-dependent diabetics to Type 2 population.
International Expansion → 30%+ Growth Ex-US
International markets (Europe, Asia, Latin America) showed 30%+ FreeStyle Libre growth as reimbursement approvals and awareness drive adoption outside the U.S.
Dividend Aristocrat → 52 Years Growth
Abbott has increased its dividend for 52 consecutive years with current 2.0% yield, demonstrating consistent cash generation and shareholder commitment.
Market Takeaway
Abbott’s April 16th earnings—just four days old—demonstrate a healthcare company firing on all cylinders with FreeStyle Libre emerging as one of the fastest-growing medical device franchises globally. The $1.8 billion in quarterly Libre sales (on pace for $7.2+ billion annually) positions it alongside blockbuster drugs in terms of revenue scale, yet it’s still early innings of market penetration with massive runway ahead.
The Libre Rio over-the-counter launch represents a strategic masterstroke that could transform the business economics. Previously, FreeStyle Libre required a prescription and insurance coverage, limiting adoption to the 8 million insulin-dependent diabetics whose doctors actively prescribed CGMs. By launching an OTC version at $49 for a two-week sensor (versus $75-100 for prescription versions), Abbott opened the market to the 100+ million Type 2 diabetics who manage their condition through diet, exercise, and oral medications but want to understand how foods affect their glucose levels. The $150 million in sales during the first two months suggests strong consumer demand, and this represents incremental growth on top of the prescription business. The international growth of 30%+ demonstrates that FreeStyle Libre’s competitive advantages versus Dexcom and Medtronic aren’t U.S.-specific. European healthcare systems and Asian countries are increasingly reimbursing CGMs as clinical evidence shows they reduce costly diabetes complications like amputations, kidney disease, and vision loss. As more countries add CGMs to reimbursement formularies, Abbott’s first-mover advantage and cost leadership (Libre sensors are 30-40% cheaper than Dexcom) position it to capture the majority of new markets. The diversified business beyond diabetes care provides defensive characteristics—nutrition (Ensure, Pedialyte), established pharmaceuticals (generic drugs in emerging markets), diagnostics, and cardiovascular devices generate $8+ billion in quarterly revenue with stable growth, providing ballast if diabetes growth moderates. Abbott’s 52-year dividend growth streak reflects exceptional capital allocation and cash flow generation, with the company producing $8+ billion in annual free cash flow that funds dividends, R&D, and bolt-on acquisitions. Trading at reasonable valuations around 21-23x forward earnings for a company growing high-single-digits with a 2% yield and exposure to diabetes care, Abbott offers quality healthcare exposure with multiple growth drivers and defensive business characteristics.